Fish acute toxicity syndrome

Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference

Retrieved on: 
Thursday, May 26, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, ASMS, CSF, Data analysis, Software, American Society for Mass Spectrometry, Fish acute toxicity syndrome, Yale School of Medicine, Machine learning, Proteome, University of Copenhagen, Proteomics, Patient, Environment, Mass spectrometry, SLE, Solution, Buck, Health, GLP, Johns Hopkins University, HRM, Society, Lupus, Trial of the century, AD, Research, Algorithm, Buck Institute for Research on Aging, Plasma, Conference, DIA, CDK, University, Biomarker, Drug development, ACS Chemical Biology, Protein, Proteoform, Drug discovery, Acquisition, Artificial intelligence, Data-independent acquisition, GCP, AstraZeneca, Body fluid, Medical imaging, Pharmaceutical industry, Fine chemical, Online shopping

Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration.

Key Points: 
  • Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration.
  • Our major contribution to the ASMS scientific program once again highlights our relentless commitment to innovation in mass spectrometry-based proteomics, said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys.
  • "With our Spectronaut 16 release, we continue to drive progress in DIA proteomics, and our TrueDiscovery and TrueTarget presentations demonstrate the utility of our research platforms for drug discovery and clinical trials.
  • At this years ASMS conference, Biognosys will commemorate the 10th anniversary of its flagship software, Spectronaut, with the launch of Spectronaut 16 in two breakfast seminars.

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, May 10, 2022
Board, Immune system, Sensei, IND, NASDAQ, GLOBE, VISTA, Safety, Research, Toxicology, Tumor microenvironment, Immunotherapy, ATP, Administration, Cancer, GMP, Blood, Therapy, CD39, Research and development, R, Congress, Northwest Biotherapeutics, G&A, Fish acute toxicity syndrome, Growth, Tumor-associated macrophage, Pharmaceutical industry, Vaccine, Online gambling, Video game, VSIG4

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates.

Key Points: 
  • BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates.
  • Recent updates for SNS-101 include:
    In April 2022 Sensei presented preclinical data demonstrating that SNS-101 had a favorable pharmacokinetic profile in a single-dose mouse model.
  • In January 2022, Sensei announced the promotions of Erin Colgan to Chief Financial Officer and Robert Pierce, M.D., to Chief R&D Officer.
  • Net Loss: Net loss was $12.4 million, for the quarter ended March 31, 2022, compared to $8.0 million for the quarter ended March 31, 2021.

Biognosys Presenting Data on its TrueDiscovery™ and TrueTarget™ Proteomics Platforms at the AACR Annual Meeting 2022

Retrieved on: 
Thursday, March 31, 2022
Oncology, Health, Medical Devices, Research, Science, Pharmaceutical, Biotechnology, Drug development, DIA, NeoGenomics, GLP, CDK9, AACR, Research, Proteome, American Association, Environment, Proteoform, Health, EGFR, Software, Association, American Association for Cancer Research, BRD4, GCP, HRM, Drug discovery, Fish acute toxicity syndrome, Solution, Efficiency, Data-independent acquisition, Protein, Proteomics, Disease, Pharmaceutical industry, Online shopping, Fine chemical, TRUEDISCOVERY™, TRUETARGET™, BIOGNOSYS

The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery and TrueTarget.

Key Points: 
  • The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery and TrueTarget.
  • Our AACR data shows how Biognosys has been able to establish mass spectrometry-based proteomics technology to provide detailed and unbiased insights about the proteome.
  • The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
  • TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.

Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update

Retrieved on: 
Thursday, November 4, 2021
Hematology, Society, SITC, Merck & Co., Expansion, Cancer, Private Securities Litigation Reform Act, Therapy, Autoimmunity, Fish acute toxicity syndrome, Clinical trial, Merck, Security (finance), NASDAQ, De novo, Technology, ASH, Inflammation, Risk, Senior, D, COVID-19, Administration, 2021 Essex County Council election, Forward-looking statement, Growth, Lymphatic system, ACR, Sale, Protein, U.S. Securities and Exchange Commission, GLOBE, Mace Head Atmospheric Research Station, SEC, Poster, Patient, American College, Neoplasm, Fine chemical, Medical device, Pharmaceutical industry, Vaccine

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter ended September 30, 2021.

Key Points: 
  • Upcoming presentations at ACR, SITC, and ASH to highlight preclinical data
    SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter ended September 30, 2021.
  • R&D Expenses: Research and development expenses for the third quarter of 2021 increased to $9.9 million from $6.2 million for the third quarter of 2020.
  • G&A Expenses: General and administrative expenses for the third quarter of 2021 increased to $5.6 million from $3.9 million for the third quarter of 2020.
  • Net Loss: Net loss for the third quarter of 2021 was $15.4 million compared to a net loss of $2.2 million in the third quarter of 2020.

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

Retrieved on: 
Thursday, September 23, 2021
Technology, WuXi Biologics, Patent, News, Clinical trial, OTCQB, Hematology-Oncology and Stem Cell Transplantation Research Center, Vaccine, Deutsch, II, DNP, Fish acute toxicity syndrome, CDMO, CSE, COVID-19, Patient, Angiotensin, MD, Private Securities Litigation Reform Act, Heart, Toxicity, Marketing, Immunotherapy, FRA, Legislation, Company, Merck, Risk, Journal, Millipore, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Thrombosis, Human, Hapten, RBD, ACE2, Forward-looking statement, Platelet factor 4, Myocarditis, Pharmaceutical industry

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine.

Key Points: 
  • Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • David Berd, MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized.
  • BioVaxys is currently finalizing arrangements with a major US academic research institution who will be collaborating with the Company on the study.

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

Retrieved on: 
Thursday, September 23, 2021
Technology, WuXi Biologics, Patent, News, Clinical trial, OTCQB, Hematology-Oncology and Stem Cell Transplantation Research Center, Vaccine, Deutsch, II, DNP, Fish acute toxicity syndrome, CDMO, CSE, COVID-19, Patient, Angiotensin, MD, Private Securities Litigation Reform Act, Heart, Toxicity, Marketing, Immunotherapy, FRA, Legislation, Company, Merck, Risk, Journal, Millipore, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Thrombosis, Human, Hapten, RBD, ACE2, Forward-looking statement, Platelet factor 4, Myocarditis, Pharmaceutical industry

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine.

Key Points: 
  • Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • David Berd, MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized.
  • BioVaxys is currently finalizing arrangements with a major US academic research institution who will be collaborating with the Company on the study.